Dr. Chloé Xu

Oncology pharmacist · Gustave Roussy · France (FR) · Oncology

Tier 2STK-0044GoodOwner MSL MTMei Tanaka

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC
Scientific interests: irAE managementBrain metastases
Engagement preference: Either
Advisory boards: 0
Publications: 15
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 2: 2 per year (assumption)

Last engaged: 06 Sept 2026 (9 days ago)
Next planned contact: 08 Mar 2027
Last 6 months vs target: 100%
3 of 1 expected engagements

Insights from this stakeholder (1)

INS-0010PD-L1 testing turnaround
11 Aug 2026 · Education need
HighAction in progress

Engagement history (3)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
06 Sept 2026	Investigator meeting	In person	Mei Tanaka	Vantrexa	Brain-metastasis subgroup dataSequencing after progression+1	0	—	Reviewed	ENG-0100
25 Aug 2026	Scientific exchange	In person	Mei Tanaka	Vantrexa	PD-L1 testing turnaroundSequencing after progression	0	—	Reviewed	ENG-0102
09 Aug 2026	Congress meeting	In person	Mei Tanaka	Vantrexa	PD-L1 testing turnaround	1	—	Reviewed	ENG-0112

Timeline

06 Sept 2026
Investigator meeting
Brain-metastasis subgroup data, Sequencing after progression, Elderly / ECOG 2 patients
25 Aug 2026
Scientific exchange
PD-L1 testing turnaround, Sequencing after progression
09 Aug 2026
Congress meeting
PD-L1 testing turnaround

Related stakeholders (5)

Gustave Roussy

Dr. Hiroshi Zimmermann
Radiation oncologist
Tier 1
Dr. William Ivanova
Radiation oncologist
Tier 1
Dr. Ulrich Kimura
Oncology pharmacist
Tier 1
Dr. Yuki Castellano
Academic nephrologist
Tier 3
Dr. Javier Kimura
Renal pathologist
Tier 3